BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation

Reuters
20 Nov 2024
BRIEF-Pasithea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Safety Review Committee (Src) Recommendation

Nov 20 (Reuters) - Pasithea Therapeutics Corp KTTA.O:

  • PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE $(SRC)$ RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER

  • PASITHEA THERAPEUTICS CORP - SRC RECOMMENDS ESCALATION TO 15MG DOSE LEVEL

  • PASITHEA THERAPEUTICS CORP - TO PROCEED TO COHORT 4, 15MG CAPSULE FOR PAS-004

Source text: ID:nGNXcgPYy0

Further company coverage: KTTA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10